CAPLIPOINT

Feb 26 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• CAPLIN POINT LABORATORIES - GETS USFDA APPROVAL FOR BRIMONIDINE TARTRATE, TIMOLOL MALEATE

• CAPLIN POINT LABORATORIES - UNIT GETS US FDA NOD FOR GLAUCOMA DRUGS

Source text: ID:nBSE4ZXxt5

Further company coverage: CAPL.NS

(([email protected];))

** Shares of Caplin Point Laboratories CAPL.NS climb ~5% to 2,204.20 rupees

** Drugmaker's unit gets U.S. FDA nod for its copycat version of heart disorder drug Pronestyl

** Drug used for treating patients with arrhythmia, which is abnormal heart rhythm

** Stock gained ~84% in 2024

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of drugmaker Caplin Point Laboratories CAPL.NS rise about 2%

** Latin America and Africa-focussed co says the U.S. Food and Drug Administration conducted an unannounced inspection at its unit's Gummidipoondi facility in August 2024

** The inspection was concludes with zero 483 observations, co says

** Stock surged over 84% in 2024

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

Jan 6 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• CAPLIN POINT LABORATORIES - RECEIVES EIR FROM FDA FOR GUMMIDIPOONDI FACILITY

• CAPLIN POINT LABORATORIES - USFDA INSPECTION CONCLUDED WITH ZERO 483 OBSERVATIONS

Source text: ID:nNSE5NFcYs

Further company coverage: CAPL.NS

(([email protected];))

Dec 16 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• CAPLIN STERILES GETS USFDA APPROVAL FOR DIFLUPREDNATE OPHTHALMIC EMULSION

Source text: ID:nBSE45J10K

Further company coverage: CAPL.NS

(([email protected];;))

** Shares of Caplin Point Laboratories CAPL.NS jump ~12% to 1,771 rupees, its highest since May 2014

** Brazil's health regulator Anvisa concluded inspection of co's manufacturing facility in Tamil Nadu, with zero observations

** The facility includes injectables and ophthalmic manufacturing

** Brazil is an important part of our expansion plans in Latin America and this clearance opens the door to the largest market in that geography, said Caplin Point Laboratories Chairman C.C. Paarthipan

** Stock eyes busiest trading session since Sept. 2021, volumes at 16.8x the 30-day avg

** Including session's gains, stock up ~31% YTD

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Aug 16 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• COMPLETION OF INSPECTION BY ANVISA-BRAZIL AT FACILITY OF UNIT

• INSPECTION BY ANVISA-BRAZIL CONCLUDED WITH ZERO OBSERVATIONS

Source text for Eikon: ID:nBSE2Htcvw

Further company coverage: CAPL.NS

(([email protected];))

Aug 9 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• COMPLETION OF US FDA INSPECTION AT FACILITY OF CAPLIN STERILES

• INSPECTION CONCLUDED WITH ZERO OBSERVATIONS

Source text for Eikon: ID:nBSE8dhlPG

Further company coverage: CAPL.NS

(([email protected];))

Aug 8 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• CAPLIN POINT LABS - CAPLIN STERILES GETS USFDA APPROVAL FOR TIMOLOL MALEATE OPHTHALMIC SOLUTION USP

Source text for Eikon: ID:nBSE25gMgY

Further company coverage: CAPL.NS

(([email protected];))

Aug 7 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• CAPLIN POINT LABORATORIES JUNE-QUARTER CONSOL NET PROFIT 1.24 BILLION RUPEES

• CAPLIN POINT LABORATORIES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.59 BILLION RUPEES

• CAPLIN POINT LABORATORIES FINAL DIVIDEND 2.5 RUPEES PER SHR

• CAPLIN POINT LABORATORIES - APPROVED RE-APPOINTMENT OF SRIDHAR GANESAN AS MD

Source text for Eikon: [ID:]

Further company coverage: CAPL.NS

(([email protected];))

May 24 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• GRANT OF USFDA APPROVAL

• CAPLIN STERILES GETS USFDA APPROVAL FOR PHENYLEPHRINE HYDROCHLORIDE OPHTHALMIC SOLUTION USP

Source text for Eikon: ID:nBSE5xJzym

Further company coverage: CAPL.NS

(([email protected];))

April 16 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• CAPLIN STERILES GETS USFDA APPROVAL FOR OFLOXACIN OPHTHALMIC SOLUTION

Source text for Eikon: ID:nBSEbxmk5g

Further company coverage: CAPL.NS

(([email protected];))

March 28 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• CAPLIN STERILES GETS USFDA APPROVAL FOR KETOROLAC TROMETHAMINE OPHTHALMIC

• GRANT OF FINAL APPROVAL FROM USFDA FOR ANDA KETOROLAC TROMETHAMINE OPHTHALMIC SOLUTION 0.5%

Source text for Eikon: ID:nBSE6BLKVV

Further company coverage: CAPL.NS

(([email protected];))

March 27 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• COMMENCEMENT OF OPERATIONS BY CAPLIN ONE LABS

• CAPLIN GROUP COMPLETES NEW ONCOLOGY (ANTI-CANCER) FACILITY

• UNIT WILL FOCUS ON MANUFACTURING RANGE OF ORAL SOLID DOSAGE ONCOLOGY PRODUCTS

• PLANS TO EXPAND PORTFOLIO TO OVER 50 ONCOLOGY PRODUCTS PROGRESSIVELY

• ONCOLOGY PRODUCTS WILL BE TARGETED AT LATIN AMERICAN COUNTRIES INITIALLY

• IN MEDIUM TERM, TO LAUNCH PRODUCTS IN REGULATED MARKETS SUCH AS US, EU, MEXICO, OTHERS

• INJECTABLE DIVISION TO COMMENCE OPERATIONS IN NEXT FEW MONTHS

Source text for Eikon: ID:nBSE4N2lKR

Further company coverage: CAPL.NS

(([email protected];))

** Shares of Caplin Point Laboratories CAPL.NS rise 5% to 1,502 rupees

** The pharma co said on Friday its Q3 consol net profit rose 20%, rev from ops up 17% Y/Y

** EBITDA margin expanded to 35.2% from 32% year ago

** More than 183,000 shares change hands, 1.3x its 30-day avg

** CAPL up ~5% so far this month, on track for fourth consecutive month of gains

** Stock gained ~32% in Dec-quarter, its third straight quarterly gain

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

** Shares of pharma co Caplin Point Laboratories CAPL.NS rise as much as 5.8% to 1,470 rupees, hitting a record high; last up 2%

** Caplin group signs memorandum of understanding with Tamil Nadu government for investment of 7 billion rupees ($84.24 million) in various projects for 5 years

** Stock trading above its 50-, 100-, and 200-day moving averages since Nov

** More than 240,000 shares change hands, 1.8x the 30-day avg

** Stock gained about 90% in 2023, best year since 2015

($1 = 83.0950 Indian rupees)

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

Jan 8 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• SIGNED MOU WITH GUIDANCE

• CAPLIN GROUP ANNOUNCES STRATEGIC INVESTMENT OF 7 BILLION RUPEES IN STATE OF TAMIL NADU

Source text for Eikon: ID:nBSE1rzjSj

Further company coverage: CAPL.NS

(([email protected];;))

Nov 9 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• INDIA'S CAPLIN POINT LABORATORIES LTD SEPT-QUARTER CONSOL NET PROFIT 1.16 BILLION RUPEES VERSUS PROFIT 920.3 MILLION RUPEES

• CAPLIN POINT LABORATORIES LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.1 BILLION RUPEES VERSUS 3.59 BILLION RUPEES

Source text for Eikon: ID:nBSE51VKLF

Further company coverage: CAPL.NS

(([email protected];))

Sept 20 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• GRANT OF FINAL APPROVAL BY USFDA FOR ANDA NOREPINEPHRINE BITARTRATE INJECTION USP, TO UNIT

Further company coverage: CAPL.NS

(([email protected];))

Sept 4 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• CAPLIN STERILES RECEIVES EIR FROM US FDA

• EIR RECEIVED FOR UNIT'S INJECTABLE AND OPHTHALMIC MANUFACTURING UNIT LOCATED AT GUMMIDIPOONDI, CHENNAI

• UNIT UNDERWENT AN INSPECTION FROM US FDA DURING MAY 22ND - MAY 31ST

• INSPECTION CLASSIFICATION WAS DETERMINED BY AGENCY AS VOLUNTARY ACTION INDICATED

Source text for Eikon: ID:nBSE2pVj8W

Further company coverage: CAPL.NS

(([email protected];))

Aug 7 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• DIVIDEND OF 2.5 RUPEES PER SHARE

• INDIA'S CAPLIN POINT LABORATORIES JUNE-QUARTER CONSOL NET PROFIT 1.03 BILLION RUPEES VERSUS PROFIT 849.9 MILLION RUPEES

• CAPLIN POINT LABORATORIES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.95 BILLION RUPEES VERSUS 3.46 BILLION RUPEES

Source text for Eikon: ID:nBSE7WDZzD

Further company coverage: CAPL.NS

(([email protected];;))

Aug 3 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• UNIT APPROVED INCORPORATION OF WHOLLY OWNED SUBSIDIARY IN US

Source text for Eikon: ID:nBSE83g4vW

Further company coverage: CAPL.NS

(([email protected];;))

June 12 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• UNIT CAPLIN STERILES GETS USFDA APPROVAL FOR CISATRACURIUM BESYLATE INJECTION

Source text for Eikon: ID:nBSE9sGRQS

Further company coverage: CAPL.NS

(([email protected];))

June 1 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• USFDA COMPLETED GMP AND PAI INSPECTION OF UNIT CAPLIN STERILES STERILE INJECTABLE SITE, GUMMIDIPOONDI

• AT END OF INSPECTION, FOUR OBSERVATIONS BY US FDA

• OBSERVATIONS ARE PROCEDURAL IN NATURE

Source text for Eikon: ID:nBSE2mrDt7

Further company coverage: CAPL.NS

(([email protected];))

** Shares of Caplin Point Laboratories Ltd CAPL.NS rise as much as 4.57% to 770 rupees, highest since Dec.6

** Pharma firm reports 29% Y/Y jump in Q4 profit on a 15% increase in revenue from ops, while core profit margin expands

** Relative strength index is 74, suggesting the stock may be overbought

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

May 12 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS:

• CAPLIN STERILES GETS USFDA APPROVAL FOR KETOROLAC TROMETHAMINE INJECTION

Source text for Eikon: ID:nBSE3gnbZ2

Further company coverage: CAPL.NS

(([email protected];;))